The Federal Drug Administration (FDA) alerted patients and health care professionals of multiple recalls of Zantac/ranitidine in September and October of 2019. Among others, Sandoz, Walgreens, Rite-Aid, Apotex and CVS announced recalls in September 2019 due to concerns over a “nitrosamine impurity, N-nitrosodimethylamine (NDMA)” found in the ranitidine products. Shortly thereafter, on October 8, 2019, GlaxoSmithKline (GSK),, a pharmaceutical company and creator of Zantac, announced a voluntary international recall, publicly acknowledging that unacceptable levels of NDMA were discovered in Zantac. On October 23, 2019, Sanofi and Dr. Reddy’s also issued voluntary recalls.
On April 1, 2020, the FDA issued a statement, acknowledging that the recall of all Zantac/ranitidine products and a public warning regarding the recall was necessary because the product presents a serious health risk.
NDMA was once used in the production of rocket fuel. The International Agency for Research on Cancer (IARC) has classified NDMA as a B2 (probable human) Carcinogen. It is also known as a potent hepatotoxin which can cause liver damage. According to recent testing done by the FDA on ranitidine samples from various drug manufacturers, more than half of the 18 samples tested contained unacceptably high levels of NDMA (more than 0.32 parts per million (ppm) of NDMA).
If you or a loved one were diagnosed with one of the cancers listed above and have taken Zantac for 6 months or more, you may have a legal claim for compensation. Contact our experienced attorneys to discuss your potential case.